MDNA Life Sciences Inc. (MDLS) expects to raise $14 million in an initial public offering (IPO) on Wednesday, May 10th, IPO Scoop reports. The company will issue 2,500,000 shares at $5.00-$6.00 per share. EF Hutton served as the underwriter for the IPO. MDNA Life Sciences Inc. provided the following description of their company for its […]
/PRNewswire/ The "Biopsy Devices: Technologies and Global Markets" report has been added to ResearchAndMarkets.com s offering. The global market for biopsy.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarkers that are present